

# Untitled

ALIGNMENT WITH SEQ ID NO: 2

ABN99362

ID ABN99362 standard; DNA; 1959 BP.

XX

AC ABN99362;

XX

DT 08-AUG-2002 (first entry)

XX

DE Human secreted protein (SECP) coding sequence 3.

XX

KW Human; secreted protein; SECP; SECP expression; gene therapy;  
KW protein therapy; immune system disorders; AIDS; thymic hypoplasia;  
KW anaemia; asthma; Crohn's disease; neurological disorder; epilepsy;  
KW Huntington's disease; dementia; Parkinson's disease; Down's syndrome;  
KW developmental disorder; cell proliferative disorder; cancer; ds; gene.

XX

OS Homo sapiens.

XX

PN V0200226982-A2.

XX

PD 04-APR-2002

XX

PF 25-SEP-2001; 2001WD-US030042.

XX

PR 29-SEP-2000; 2000US-0236869P.

PR

PR 11-OCT-2000; 2000US-0239812P.

PR

PR 12-OCT-2000; 2000US-0240108P.

PR

PR 17-OCT-2000; 2000US-0241282P.

PR

PR 20-OCT-2000; 2000US-0242218P.

XX

PA (INCY-) INCYTE GENOMICS INC.

XX

PI Yue H, Tang YT, Nguyen DB, Yao MG, Xu Y, Tribouley CM,  
PI Sanjanwala MS, Valia NK, Baughn MR, Sapperstein SK, Lal P;  
PI Thornton M, Gandhi AR, Rankumar J, Elliott VS, Arvizu C;  
PI Thangavelu K, Getzen KJ, Ding L, Au-Young J, Tran B, Policky JL;  
PI Lee S, Lu DAM, Burford N, Warren BA, Gururajan R, Duggan BM  
PI Honchell CD, Hatfield AJA;

XX

DR WPI; 2002-394239/42.

DR

DR P-PSDB; ABP43479.

XX

PT New human secreted proteins, useful for diagnosing, treating or  
PT preventing immune system disorders (e.g. Crohn's disease), neurological  
PT disorders (e.g. Parkinson's disease), or cell proliferative disorders  
PT (e.g. cancers).

XX

PS Claim 5; Page 197; 238pp; English.

XX

CC The invention comprises the amino acid and coding sequences of human  
CC secreted proteins (SECP). The SECP DNA and amino acid sequences of the  
CC invention are useful for treating/preventing disorders associated with  
CC decreased or elevated expression of SECP. The SECP DNA and protein  
CC sequences are specifically useful for treating/preventing (i.e. gene  
CC therapy and protein therapy): immune system disorders (e.g. AIDS, thymic  
CC hypoplasia, anaemia, asthma or Crohn's disease); neurological disorders  
CC (e.g. epilepsy, Huntington's disease, dementia or Parkinson's disease);  
CC developmental disorders (e.g. Down's syndrome); and cell proliferative  
CC disorders (e.g. cancer). The nucleotides ABN99360 - ABN99428 encode the  
CC human secreted proteins (SECP) of the invention

## XX

Query Match 98.0% Score 1913.8; DB 6; Length 1959;  
Best Local Similarity 99.9% Pred. No. 0;  
Matches 1915; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Page 2

[illegible]

# Untitled

Qy 1836 ACAGCTCAGTGATGAAGTGGGGAGGTGGGAGAGGCGCTTTGCTAGGGGTGGT 1895  
 Db 1801 ACAGCTCAGTGATGAAGTGGGGAGGTGGGAGAGGCGCTTTGCTAGGGGTGGT 1860  
 Qy 1896 TGGCCTGTATACATGATCCAGTCTGTGACTACACGCCAACCTGAATAAGCGGTTTT 1952  
 Db 1861 TGGCCTGTATACATGATCCAGTCTGTGACTACACGCCAACCTGAATAAGCGGTTTT 1917

## ALIGNMENT WITH SEQ ID NO: 66

ABP43479

ID ABP43479 standard; protein; 204 AA

XX

AC

XX

DT

DT

XX

DE

XX

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

CS

XX

PN

XX

PD

XX

PF

XX

PR

PR

PR

PR

PR

PR

XX

PA

XX

PI

PI

PI

PI

PI

PI

XX

DR

DR

15-JUN-2007 (revised)

08-AUG-2002 (first entry)

Human secreted protein (SCEP) 3.

Human; secreted protein; SEOP; SEOP expression; gene therapy;  
 protein therapy; immune system disorders; AIDS; thymic hypoplasia;  
 anemia; asthma; Crohn's disease; neurological disorder; epilepsy;  
 Huntington's disease; dementia; Parkinson's disease; Down's syndrome;  
 developmental disorder; cell proliferative disorder; cancer; BOND\_PC;  
 chromosome 20 open reading frame 102;  
 chromosome 20 open reading frame 102 [Homo sapiens]; C20orf102;  
 dJ118M15.2; hypothetical protein LOC128434;  
 hypothetical protein LOC128434 [Homo sapiens];  
 chromosome 20 open reading frame 102, isoform CRA\_a;  
 chromosome 20 open reading frame 102, isoform CRA\_a [Homo sapiens];  
 hypothetical protein; hypothetical protein [Homo sapiens];  
 unnamed protein product; unnamed protein product [Homo sapiens]; GC4872;  
 GC7166.

Homo sapiens.

W0200226982-A2.

04-APR-2002.

25-SEP-2001; 2001W0-US030042.

29-SEP-2000; 2000US-0236869P.

11-OCT-2000; 2000US-0239812P.

12-OCT-2000; 2000US-0240108P.

17-OCT-2000; 2000US-0241282P.

20-OCT-2000; 2000US-0242218P.

(INCY-) INCYTE GENOMCS INC.

Yue H, Tang YT, Nguyen DB, Yao MG, Xu Y, Tribouley CM,  
 Sanjanwalla MS, Valia NK, Baughn MR, Sapperstein SK, Lal P;  
 Thornton M, Gandhi AR, Rankumar J, Elliott VS, Arvizu C;  
 Thangavelu K, Getzen KJ, Ding L, Au-Young J, Tran B, Policky JL;  
 Lee S, Lu DAM, Burford N, Warren BA, Gururajan R, Duggan BM  
 Honchell CD, Hafalia AJA;

VPI: 2002-394239/42.

N-PSDB; ABN99362.

# Untitled

DR PC: NCBI; gi18079321.  
DR PC: SW:SSPROT; C96N03.

XX  
PT New human secreted proteins, useful for diagnosing, treating or  
PT preventing immune system disorders (e.g. Crohn's disease), neurological  
PT disorders (e.g. Parkinson's disease), or cell proliferative disorders  
PT (e.g. cancers).

XX  
PS Claim 1; Page 151-152; 238pp; English.

XX  
CC The invention comprises the amino acid and coding sequences of human  
CC secreted proteins (SECP). The SECP DNA and amino acid sequences of the  
CC invention are useful for treating/preventing disorders associated with  
CC decreased or elevated expression of SECP. The SECP DNA and protein  
CC sequences are specifically useful for treating/preventing (i.e. gene  
CC therapy and protein therapy): immune system disorders (e.g. AIDS, thymic  
CC hypoplasia, anaemia, asthma or Crohn's disease); neurological disorders  
CC (e.g. epilepsy, Huntington's disease, dementia or Parkinson's disease);  
CC developmental disorders (e.g. Down's syndrome); and cell proliferative  
CC disorders (e.g. cancer). The proteins ABP43477 - ABP43543 represent the  
CC human secreted proteins (SECP) of the invention

CC  
CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed  
CC information from BOND.

XX  
SQ Sequence 204 AA;

Query Match 100.0% Score 1092; DB 5; Length 204;  
Best Local Similarity 100.0% Pred. No. 1.7e-92;  
Matches 204; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGAPLAVALGALHYLALFLQLGGATRPAGHAPWDNHVSGHALFTETPHDMTARTGEDVEM 60  
Db 1 MGAPLAVALGALHYLALFLQLGGATRPAGHAPWDNHVSGHALFTETPHDMTARTGEDVEM 60  
Qy 61 ACSFRSGSPSYSL EIQWVVRSHRDWTDKQAVASNLKASQCEDAGKEATKI SVVKVVG 120  
Db 61 ACSFRSGSPSYSL EIQWVVRSHRDWTDKQAVASNLKASQCEDAGKEATKI SVVKVVG 120  
Qy 121 SNI SHIKRLRSRVKPTDEGTYECRVI DFSDGKARHHKVKAYLRVCPGENSVLHLPEAPPAA 180  
Db 121 SNI SHIKRLRSRVKPTDEGTYECRVI DFSDGKARHHKVKAYLRVCPGENSVLHLPEAPPAA 180  
Qy 181 PAPPPPKPGKELRKRSVDQEA CSL 204  
Db 181 PAPPPPKPGKELRKRSVDQEA CSL 204